StemCellPatents.com Recently Added Stem Cell Patents

Methods to mobilize progenitor/stem cells

Anormed, Inc. (Langley, CA) — 2007-02-04T17:05:35-05:00

The reason why bone marrow cells home into the bone after intravenous administration is because a continuous production of Stromal Derived Factor-1 (SDF-1) by the bone marrow stromal compartments. The gradient of SDF-1 is also retains the early CD34+ bone marrow hematopoietic stem cells in the bone marrow. The current patent covers compositions of matter that inhibit the interaction between SDF-1 and its...

Injectable hyaluronic acid derivative with pharmaceuticals/cells

Fidia Advanced Biopolymers, SRL. (Abano Terme, IT) — 2007-01-06T15:18:24-05:00

This patent covers specific types of hyaluronic acid derivatives that are useful for administering cells into a soft tissue that is injured. Specifically, the patent is useful for treatment of intra-articular injuries by providing a means to administer cells so that the cells will be able to take the particular in vivo shape that is unique to the patient being treated. The patent has 2 independent claims. The first is a method of treatment claim, which provides at least one type of...

SCF antibody compositions and methods of using the same

Amgen Inc. (Thousand Oaks, CA) — 2006-10-16T17:43:19-05:00

Amgen has developed a strong patent portfolio covering the hematopoietic stimulating cytokine called Stem Cell Factor. Subsequently it was demonstrated that stem cell factor is capable of stimulating a variety of other stem cells in addition to hematopoietic stem cells. As part of its IP portfolio covering stem cell factor, Amgen has patented antibodies to the cytokine. This current patent covers polyclonal and monoclonal antibodies to stem cell factor from human or from other...

Methods of use of FGF homologs

ZymoGenetics, Inc. (Seattle, WA) — 2006-10-16T12:53:04-05:00

This patent covers the use of zFGF-5 (currently known as FGF-18) for expansion in vitro and in vivo of chondrocytes and neural stem cells. According to the Zymogenetics website, FGF-18 is out-licensed to Serono for use in cartilage repair and stroke. The product is in preclinical phases of testing. While the specification provides numerous uses for FGF-18, the claims are restricted to one independent claim...

Sirtuin modulating compounds

Sirtris Pharmaceuticals, Inc. (Cambridge, MA) — 2005-08-04T21:21:21-05:00

This patent covers the composition of matter for novel compounds that are useful for modulation of sirtuins. Sirtuins are a class of proteins that act as histone deacetylase inhibitors. Why there is great interest in modulating these enzymes is because the SIR2 members of this family have been demonstrated to play a critical role in life extension associated with caloric restriction. This patent is assigned to the company Sirtris, which recently went public...

In vitro mass production of human erythroid cells from the blood of normal donors and thalassemic patients

Istituto Superiore di Sanita (Rome, IT) — 2005-02-26T00:00:00-05:00

This patent teaches how to generate large quantities of erythroid cells in vitro. This is useful for nuclear disasters or situations where large quantities of red blood cells are needed for transfusion purposes. This is a very interesting invention since it uses as the starting population blood cells and not bone marrow. The invention has 1 independent claim covering the method of generating erythroid cells. Specifically, the claim covers taking blood cells of a "low density"...

Methods for assisting recovery of damaged brain and spinal cord using arrays of X-ray microplanar beams

Brookhaven Science Associates, LLC (Upton, NY) — 2005-02-10T21:31:14-05:00

One of the problems with cell therapy after injury is the possibility of accelerating scar tissue formation. The current patent teaches the use of X-rays, administered by parallel micro-beams at doseages that are sufficient to remove inhibitors of regeneration. The patent also discloses the use of exogenous stem cells in combination with the X-rays in order to accelerate healing.

Methods for assisting recovery of damaged brain and spinal cord using arrays of X-Ray microplanar beams

Brookhaven Science Associates, LLC (Upton, NY) — 2005-02-10T15:21:29-05:00

It has always been the belief of StemCellPatents.com that the future of stem cell therapeutics is not only in the development and use of stem cell types, but the integration of stem cells with other modalities to attain synergy. For example, while FDA/EMEA development of cellular product candidates takes years and hundreds of millions of dollars, the same, or very similar stem cell products are already commercialized clinically by off-shore institutions. Clinical...

Three dimensional bioengineered smooth muscle tissue and sphincters and methods therefor

The Regents of The University of Michigan (Ann Arbor, MI) — 2004-11-24T22:43:08-05:00

This patent covers methods of producing artificial sphincters. Specifically, smooth muscle cells are grown on an extracellular matrix that is placed on a tissue culture vessal coated with polydimethyl siloxane and a mold made of a cylindrical shape which is coated with the same material. Examples of extracellular matrices useful for the invention include fibrin. The patent covers a variety of sphincters including internal anal and sphincters of the gastrointestinal...

Compositions, systems and methods for treatment of defects in blood vessels

Microvention, Inc. (Aliso Viejo, CA) — 2004-11-16T11:49:55-05:00

Vascular aneurysms are thinning of blood vessel walls, which is usually associated with vessel trauma, non-specific degeneration, atherosclerosis, or infection. The term "aneurysm" comes from the Latin "aneurysma" which means "dilation". Aneurysms are hazardous because of the potential to burst. They are usually prevelant in the aorta or cerebral arteries. The current patent provides methods of treating blood vessel defects, including aneurysms, through introducing various...

Cord blood and placenta collection kit

Celgene Corporation (Summit, NJ) — 2004-09-23T01:30:48-05:00

Celgene, through its wholly owned subsiduary Anthrogenesis (now called Celgene Cellular Therapeutics) has been active in the cord blood IP area, through patents covering innovative methods of extracting stem cells from the placental matrix itself . In the current patent, Celgene covers a kit for collecting not only the umbilical cord blood itself, but also the whole placenta, this way no material is wasted and additional...

Musculo-skeletal implant having a bioactive gradient

Depuy Spine, Inc. (Raynham, MA) — 2004-09-01T20:30:42-05:00

It is known that stem cells migrate towards injured tissue in response to chemotactic gradients. For example the basal SDF-1 gradient made by bone marrow stromal cells is why it is possible to achieve hematopoietic reconstitution by injecting donor cells intravenously. Similarly, SDF-1 acts as a gradient to call stem cells into damaged myocardium after a heart attack.

The current patent is aimed at teaching the person of skill in the art how to...

Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity

Praecis Pharmaceuticals, Inc. (Waltham, MA) — 2004-08-13T14:22:35-05:00

It is known that Sphingosine-1-phosphate mediates migration of mesenchymal stem cells. However, there are numerous receptors by which the effects of sphingosine-1-phosphate are mediated. While the sphingosine-1-phosphate receptor 1 is associated with migration, other activation of other receptors (such as sphingosine-1-phosphate receptors 2-5) is associated with adverse events such as hypotension or bradycardia. The current patent...

Genome mutation by intron insertion into an embryonic stem cell genome

Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) — 2004-06-10T01:50:46-05:00

Genetic manipulation of ES cells provides a powerful method for developing unique cell line models of various human diseases. More clinically applicable is the possibility of specifically producing mutations in genes that elicit rejection of ES cells, so as to generate "universal donor" stem cells. This patent teaches ways of generating mutations in exons of genes in ES cells by introduction of intronic sequences. Insertion of intronic sequences is provided by the use of targeted...

Pluripotent adult stem cells

None Stated — 2004-05-20T11:13:50-05:00

This patent covers a stem cell that is positive for expression of CD13, CD34, CD56 and CD117, negative for CD10. Dependent claims further cover the phenotype of CD2, CD5, CD14, CD19, CD33, CD45, and DRII negative, CD13,CD34, CD56, CD90, CD117 positive, and CD2, CD3, CD10, CD14, CD16, CD31, CD33, CD45 and

Method of treating mood disorders and/or anxiety disorders by brain stimulation

Advanced Neuromodulation Systems, Inc. (Plano, TX) — 2004-04-30T03:13:21-05:00

While studies have already demonstrated the ability of adult stem cells and embryonic stem cells to differentiate into neurons, the possibility of modulating new neurons to integrate into existing neurons, as well as enhance activity, is the philosophical "next stem". The current patent covers the use of a pulse generating electrode that is implanted in the inferior...

Use of Xenopus laevis oocytes a microincubators

University of South Florida (Tampa, FL) — 2004-04-21T13:33:19-05:00

The concept of "de-differentiation" of cells is very attractive from a therapeutic perspective since it offers the possibility of generating autologous stem cells from somatic tissue. If one could devise a method for generating even minute numbers of totipotent stem cells from autologous tissue, these cells could be expanded and used to treat almost any illness. The use of nuclear transfer for "reprogramming" an adult nucleus has previously been

Aryl-containing 5-acylindolinones, the preparation thereof and their use as medicaments

Boehringer Ingelheim International GmbH (Ingelheim, DE) — 2004-03-12T17:22:07-05:00

Although much effort in stem cell therapeutic development is being focused on administration of exogenous stem cells, one area that is generally being overlooked is methods of activating/expanding endogenous stem cells. It was recently published that the in vivo inhibition of the enzyme GSK-3 promotes hematopoietic stem cell self renewal (Trowbridge et al. Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat Med. 2006...

Modified hyaluronic acid for use in musculoskeletal tissue repair

Ethicon, Inc. (Somerville, NJ) — 2003-12-19T00:00:00-05:00

This patent is useful for making scaffolds onto which stem cells, progenitor cells, or other type of cells can be seeded, and the scaffold together with the seeded cells are implanted in vivo. Previous scaffold technologies using hyaluronic acid have the drawback of very rapid resorption in the body, not giving the cells enough time to integrate and function properly. This patent uses a novel means of extending usefulness of scaffolds. The patent has 1 independent claim which teaches how...

Preparation of a cell concentrate from a physiological solution

Smith & Nephew, Inc. (Memphis, TN) , Pall Corporation (East Hills, NY) — 2003-12-10T15:44:12-05:00

The use of bone marrow mononuclear cells as a source of stem cells has been widely described in numerous medical procedures ranging from stimulation of angiogenesis in patients with peripheral artery disease to treatment of terminal liver failure, to treatment of heart disease. Unfortunately the use of autologous...